Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model

Not only is the firm profit-making, but its investment in potential drug candidates has made it attractive to investors, says Louis Tse Ming Kwong of VC Asset Management Viva’s business model of …
( read original story …)

---